Lung Cancer Clinical Trial
Official title:
[18F]FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 (^18FDG) positron emission
tomography (PET)/CT scans, may help doctors predict a patient's response to treatment and
help plan the best treatment.
PURPOSE: This clinical trial is studying ^18FDG PET/CT scans to see how well they predict
response in patients undergoing chemotherapy for stage IIIB or stage IV non-small cell lung
cancer.
OBJECTIVES:
- Determine whether a metabolic response, defined as a 25% decrease in peak tumor
standardized uptake value (SUV) after the first course of chemotherapy, provides early
prediction of treatment outcome (tumor response and patient survival) in patients with
stage IIIB or IV non-small cell lung cancer undergoing platinum-based chemotherapy.
- Determine the test-retest reproducibility of quantitative assessment of tumor
fludeoxyglucose F 18 (^18FDG) uptake in these patients.
- Determine the time course of treatment-induced changes in tumor ^18FDG uptake in these
patients.
- Determine, in an exploratory analysis, changes in tumor volume during chemotherapy by
multislice CT scanning in these patients.
OUTLINE: This is a prospective, multicenter study. Patients are assigned to 1 of 3 groups.
- Group I: Patients undergo fludeoxyglucose F 18 (^18FDG) positron emission tomography
(PET)/CT scanning twice and 1-2 volumetric CT scanning (1-7 days apart) before starting
treatment with platinum-based chemotherapy. Patients undergo additional ^18FDG PET/CT
scan and a volumetric CT scan once between the first and second course of chemotherapy.
- Group II: Patients undergo ^18FDG PET/CT scan and volumetric CT scanning once before
starting treatment with platinum-based chemotherapy. Patients undergo additional ^18FDG
PET/CT scan and volumetric CT scanning once between the first and second course of
chemotherapy, and may undergo once between the second and third course of chemotherapy.
- Group III: Patients undergo ^18FDG PET/CT scanning twice (up to 1 week apart) before
starting any treatment.
In groups I and II, patients also undergo standard follow-up CT scanning every 6 weeks (i.e.,
every other chemotherapy course) for up to 18 weeks.
After completion of chemotherapy, patients are followed every 3 months for up to 1 year.
Biomarker
- Imaging: See
- provided by American College of Radiology Network.
PROJECTED ACCRUAL: A total of 285 patients will be accrued for this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|